Susan G. Kozauer, MD

Former employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey

  • 4Articles
  • 19.5KReads
  • 2023–2026Active
  • 13Collaborators
  • 26Citations

About

Susan G. Kozauer, MD, is a former employee of Intra-Cellular Therapies, a Johnson & Johnson company in Bedminster, New Jersey. Her publications from 2023 to 2026 focus on the clinical evaluation of lumateperone as adjunctive therapy in major depressive disorder and bipolar depression with mixed features, as well as its effects on sexual dysfunction. She has collaborated frequently with co-authors including Suresh Durgam, Roger S. McIntyre, Willie R. Earley, Anita H. Clayton, and Changzheng Chen.

Publications

JCP
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress

September 14, 2026

Adjunctive lumateperone 42 mg significantly improved depression and anxiety symptoms in patients with MDD with inadequate antidepressant response and anxious distress
, , , et al
JCP
Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder
Original Research

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

September 2, 2026

Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction.
, , , et al
JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al
JCP
Efficacy of Lumateperone in Bipolar Depression With Mixed Features
Original Research

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

April 24, 2023

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe